Valentina Nardi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11443302/publications.pdf

Version: 2024-02-01

88 papers	3,531 citations	218677 26 h-index	144013 57 g-index
88 all docs	88 docs citations	88 times ranked	6245 citing authors

#	Article	IF	Citations
1	Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiology, 2022, 51, 17-30.	2.0	5
2	Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data. Archives of Pathology and Laboratory Medicine, 2022, 146, 451-461.	2.5	3
3	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Advances, 2022, 6, 818-827.	5.2	5
4	Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist, 2022, 27, 82-86.	3.7	5
5	Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, , .	5.0	1
6	An unusual lymphoma involving the <scp>GI</scp> tract and bone marrow. American Journal of Hematology, 2022, 97, 1268-1269.	4.1	0
7	Nâ€terminus <scp>DUX4</scp>â€immunohistochemistry is a reliable methodology for the diagnosis of DUX4â€fused Bâ€lymphoblastic leukemia/lymphoma (Nâ€terminus <scp>DUX4 IHC</scp> for) Tj ET Q q 1 0 0 1 0.78 84314 rg BT	2.8	1
8	Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing. Leukemia and Lymphoma, 2022, , 1-5.	1.3	1
9	Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. Blood Advances, 2022, 6, 4236-4240.	5.2	6
10	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	1.4	8
11	Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica, 2021, 106, 555-564.	3.5	34
12	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. American Journal of Clinical Pathology, 2021, 155, 748-754.	0.7	9
13	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. American Journal of Surgical Pathology, 2021, 45, 895-904.	3.7	29
14	Predictive â€˜biomarker piggybackingâ€™: an examination of reflexive panâ€cancer screening with panâ€TRK immunohistochemistry. Histopathology, 2021, 79, 260-264.	2.9	7
15	Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. Journal of Molecular Diagnostics, 2021, 23, 630-636.	2.8	11
16	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
17	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. Oncologist, 2021, 26, 919-924.	3.7	6
18	Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood, 2021, 138, 2435-2440.	1.4	10

#	Article	IF	Citations
19	Myelodysplastic syndromes with no somatic mutations detected by nextâ€generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. American Journal of Hematology, 2021, 96, E420-E423.	4.1	5
20	Two In Cis Variantsâ€"Two Worlds Apart. Oncologist, 2021, 26, 997-999.	3.7	0
21	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers, 2021, 13, 5502.	3.7	2
22	Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas. Blood, 2021, 138, 398-398.	1.4	1
23	Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. Modern Pathology, 2020, 33, 560-565.	5.5	46
24	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. Journal of Molecular Diagnostics, 2020, 22, 1162-1178.	2.8	20
25	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia, 2020, 34, 3050-3054.	7.2	3
26	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Advances, 2020, 4, 3136-3140.	5.2	28
27	MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections. Frontiers in Endocrinology, 2020, 11, 480.	3.5	22
28	Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases. Human Pathology, 2020, 106, 62-73.	2.0	19
29	Clinical sensitivity and interpretation of PCR and serological COVIDâ€19 diagnostics for patients presenting to the hospital. FASEB Journal, 2020, 34, 13877-13884.	0.5	117
30	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1â€"KMT2Aâ€"YAP1 and VIMâ€"KMT2A fusions. Modern Pathology, 2020, 33, 2307-2317.	5.5	24
31	Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure. New England Journal of Medicine, 2020, 382, 1258-1266.	27.0	4
32	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Advances, 2020, 4, 445-448.	5.2	11
33	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectrum, 2020, 4, pkz094.	2.9	114
34	Clinical response to larotrectinib in adult Philadelphia chromosomeâ€"like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Advances, 2020, 4, 106-111.	5.2	23
35	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112.	4.9	102
36	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. Blood, 2020, 136, 14-14.	1.4	0

#	Article	IF	Citations
37	Rare Inherited Defects of the Complement System in Purpura Fulminans. Blood, 2020, 136, 35-36.	1.4	1
38	Premalignant Clonal Hematopoietic Proliferations. American Journal of Clinical Pathology, 2019, 152, 347-358.	0.7	3
39	Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. New England Journal of Medicine, 2019, 381, 1951-1960.	27.0	7
40	Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Human Pathology, 2019, 93, 65-73.	2.0	27
41	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
42	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist, 2019, 24, 1356-1367.	3.7	18
43	Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas. American Journal of Surgical Pathology, 2019, 43, 235-243.	3.7	29
44	Case 37-2019: A 20-Month-Old Boy with Severe Anemia. New England Journal of Medicine, 2019, 381, 2158-2167.	27.0	0
45	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Human Pathology, 2019, 86, 1-11.	2.0	24
46	Feasibility of Perioperative Microâ€“Computed Tomography of Human Lung Cancer Specimens: A Pilot Study. Archives of Pathology and Laboratory Medicine, 2019, 143, 319-325.	2.5	10
47	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	1.2	25
48	A Nanopore Sequencingâ€“Based Assay for Rapid Detection of Gene Fusions. Journal of Molecular Diagnostics, 2019, 21, 58-69.	2.8	34
49	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	1.4	6
50	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program. Blood, 2019, 134, 5371-5371.	1.4	0
51	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825.	1.4	64
52	Laboratory testing in BCRâ€ABL1â€like (Philadelphiaâ€like) Bâ€lymphoblastic leukemia/lymphoma. American Journal of Hematology, 2018, 93, 971-977.	4.1	24
53	MET Amplification in Esophageal Squamous Carcinoma. International Journal of Surgical Pathology, 2018, 26, 731-732.	0.8	2
54	Syphilis of the Aerodigestive Tract. American Journal of Surgical Pathology, 2018, 42, 472-478.	3.7	55

#	Article	IF	Citations
55	Artificial Intelligence Approach for Variant Reporting. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	2.1	13
56	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	17
57	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. New England Journal of Medicine, 2018, 379, 1946-1953.	27.0	4
58	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	12.8	80
59	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	1.4	0
60	Diagnostic workâ€up of acute myeloid leukemia. American Journal of Hematology, 2017, 92, 317-321.	4.1	18
61	A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer, 2017, 123, 1979-1988.	4.1	92
62	Case 5-2017. New England Journal of Medicine, 2017, 376, 684-692.	27.0	11
63	A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Reports, 2017, 21, 784-797.	6.4	65
64	GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Modern Pathology, 2017, 30, 1720-1727.	5.5	33
65	Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Modern Pathology, 2017, 30, 1489-1503.	5.5	93
66	Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist, 2016, 21, 1035-1040.	3.7	18
67	EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Modern Pathology, 2016, 29, 1200-1211.	5.5	38
68	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surgical Pathology Clinics, 2016, 9, 143-163.	1.7	14
69	Notch-Regulated Enhancers in B-Cell Lymphoma Activate MYC and Potentiate B-Cell Receptor Signaling. Blood, 2016, 128, 457-457.	1.4	2
70	Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. American Journal of Hematology, 2015, 90, 529-533.	4.1	5
71	Clinical Grade â€œSNaPshotâ€•Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine, 2015, 2, 71-73.	6.1	12
72	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Cancer Discovery, 2015, 5, 1058-1071.	9.4	105

#	Article	IF	Citations
73	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist, 2015, 20, 1019-1027.	3.7	112
74	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
75	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Pathology, 2015, 28, 552-563.	5.5	42
76	A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2015, 33, e15124-e15124.	1.6	0
77	Merkel Cell Carcinoma: 30-Year Experience from a Single Institution. Annals of Surgical Oncology, 2013, 20, 1365-1373.	1.5	117
78	Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment. Clinical Cancer Research, 2013, 19, 480-490.	7.0	105
79	Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 2340-2347.	1.6	89
80	Activation of PI3K Signaling in Merkel Cell Carcinoma. Clinical Cancer Research, 2012, 18, 1227-1236.	7.0	97
81	Peptides Derived From Mutated BCR-ABL Elicit T Cell Immunity In CML Patients. Blood, 2010, 116, 887-887.	1.4	1
82	FAK silencing inhibits leukemogenesis in BCR/ABLâ€transformed hematopoietic cells. American Journal of Hematology, 2009, 84, 273-278.	4.1	20
83	Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature, 2009, 460, 259-263.	27.8	938
84	Bone Marrow Adipocytes: A Novel Negative Regulator of the Hematopoietic Microenvironment.. Blood, 2007, 110, 1405-1405.	1.4	0
85	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9244-9249.	7.1	104
86	BCR-ABL Kinase Dynamics and Drug Resistance.. Blood, 2005, 106, 1996-1996.	1.4	1
87	Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Current Opinion in Hematology, 2004, 11, 35-43.	2.5	170
88	A screen to identify drug resistant variants to target-directed anti-cancer agents. Biological Procedures Online, 2003, 5, 204-210.	2.9	21